» Articles » PMID: 12605718

Influence of Hypoxia and Neoangiogenesis on the Growth of Pancreatic Cancer

Overview
Journal Mol Cancer
Publisher Biomed Central
Date 2003 Feb 28
PMID 12605718
Citations 68
Authors
Affiliations
Soon will be listed here.
Abstract

As with other solid tumors, the growth and metastasis of pancreatic cancer is critically dependent on tumor angiogenesis. A major stimulus for a tumor's recruitment of additional blood vessels is cellular hypoxia, a condition which is especially pronounced in this neoplasm. Hypoxia induces transcriptional activation of genes that alter cellular metabolism and promote neoangiogenesis. Pancreatic cancer cells have demonstrated activation of such adaptive pathways even in the absence of hypoxia. A highly-angiogenic response in this neoplasm correlates with increased tumor growth, increased metastasis, and decreased survival. Pancreatic cancers expressing high levels of vascular endothelial growth factor, a potent pro-angiogenic cytokine, also have a higher incidence of metastasis and poorer prognosis. Pancreatic cancer cells uniquely express receptors for vascular endothelial growth factor, indicating a role for an autocrine loop in tumor proliferation and invasion. Multiple experimental anti-angiogenic strategies, many of which target vascular endothelial growth factor, reduce pancreatic cancer growth, spread, and angiogenesis. Anti-angiogenic treatments for pancreatic cancer will likely be most effective when used as an integral part of a combination chemotherapeutic regimen.

Citing Articles

Inhibition of Chitinase-3-like Protein 1 Reduced Epithelial-Mesenchymal Transition and Vascular Epithelial Cadherin Expression in Oesophageal Squamous Cell Carcinoma.

Qin Y, Zhao W, Li Q, Cai Z, Wang G, Wang N Iran J Biotechnol. 2024; 22(3):e3693.

PMID: 39737205 PMC: 11682521. DOI: 10.30498/ijb.2024.394737.3693.


Local Magnetic Hyperthermia and Systemic Gemcitabine/Paclitaxel Chemotherapy Triggers Neo-Angiogenesis in Orthotopic Pancreatic Tumors without Involvement of Auto/Paracrine Tumor Cell VEGF Signaling and Hypoxia.

Maduabuchi W, Tansi F, Faenger B, Southern P, Pankhurst Q, Steiniger F Cancers (Basel). 2024; 16(1).

PMID: 38201461 PMC: 10778317. DOI: 10.3390/cancers16010033.


Microbiota in cancer: molecular mechanisms and therapeutic interventions.

Chen Z, Guan D, Wang Z, Li X, Dong S, Huang J MedComm (2020). 2023; 4(6):e417.

PMID: 37937304 PMC: 10626288. DOI: 10.1002/mco2.417.


Pancreatic Ductal Adenocarcinoma: The Characteristics of Contrast-Enhanced Ultrasound Are Correlated with the Hypoxic Microenvironment.

Wang L, Li M, Dong T, Li Y, Yin C, Nie F Diagnostics (Basel). 2023; 13(20).

PMID: 37892091 PMC: 10606620. DOI: 10.3390/diagnostics13203270.


BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis.

Huang C, Li H, Xu Y, Xu C, Sun H, Li Z Signal Transduct Target Ther. 2023; 8(1):271.

PMID: 37443111 PMC: 10344882. DOI: 10.1038/s41392-023-01478-5.


References
1.
Gluzman-Poltorak Z, Cohen T, Herzog Y, Neufeld G . Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165 [corrected]. J Biol Chem. 2000; 275(24):18040-5. DOI: 10.1074/jbc.M909259199. View

2.
Giatromanolaki A, Koukourakis M, Sivridis E, OByrne K, Gatter K, Harris A . 'Invading edge vs. inner' (edvin) patterns of vascularization: an interplay between angiogenic and vascular survival factors defines the clinical behaviour of non-small cell lung cancer. J Pathol. 2000; 192(2):140-9. DOI: 10.1002/1096-9896(2000)9999:9999<::AID-PATH693>3.0.CO;2-R. View

3.
Brown L, Detmar M, Claffey K, Nagy J, Feng D, Dvorak A . Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS. 1997; 79:233-69. DOI: 10.1007/978-3-0348-9006-9_10. View

4.
Buchler P, Reber H, Buchler M, Shrinkante S, Buchler M, Friess H . Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer. Pancreas. 2002; 26(1):56-64. DOI: 10.1097/00006676-200301000-00010. View

5.
Semenza G . HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med. 2002; 8(4 Suppl):S62-7. DOI: 10.1016/s1471-4914(02)02317-1. View